Reno protective role of amlodipine in patients with hypertensive chronic kidney disease

• Published in: World journal of nephrology 2022-05, Vol.11 (3), p.86-95
• Main Authors: Abraham, Georgi, Almeida, A, Gaurav, Kumar, Khan, Mohammed Yunus, Patted, Usha Rani, Kumaresan, Maithrayie
• Format: Article
• Language: English
• Subjects: Minireviews
• ISSN: 2220-6124; 2220-6124
• DOI: 10.5527/wjn.v11.i3.86

Chronic kidney disease (CKD) and hypertension (HTN) are closely associated with an overlapping and intermingled cause and effect relationship. Decline in renal functions are usually associated with a rise in blood pressure (BP), and prolonged elevations in BP hasten the progression of kidney function decline. Regulation of HTN by normalizing the BP in an individual, thereby slowing the progression of kidney disease and reducing the risk of cardiovascular disease, can be effectively achieved by the anti-hypertensive use of calcium channel blockers (CCBs). Use of dihydropyridine CCBs such as amlodipine (ALM) in patients with CKD is an attractive option not only for controlling BP but also for safely improving patient outcomes. Vast clinical experiences with its use as monotherapy and/or in combination with other anti-hypertensives in varied conditions have demonstrated its superior qualities in effectively managing HTN in patients with CKD with minimal adverse effects. In comparison to other counterparts, ALM displays robust reduction in risk of cardiovascular endpoints, particularly stroke, and in patients with renal impairment. ALM with its longer half-life displays effective BP control over 24-h, thereby reducing the progression of end-stage-renal disease. In conclusion, compared to other classes of CCBs, ALM is an attractive choice for effectively managing HTN in CKD patients and improving the overall quality of life.